Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52056 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Tobias Moser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria. Hauptthemen laut MEDLINE: Alemtuzumab. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective Observational real‐world study to analyze the clinical effects of alemtuzumab (ALEM) and subsequent disease‐modifying therapy (DMT) usage in multiple sclerosis (MS).
Methods
Data retrieved from the Austrian MS treatment registry (AMSTR) included baseline (BL) characteristics (at ALEM start), annualized relapse rate (ARR), 6‐month confirmed progression independent of relapse activity (PIRA; ≥ 0.5‐point Expanded Disability Status Scale (EDSS) score increase), 6‐month confirmed disability improvement (CDI; ≥ 0.5‐point EDSS decrease), and safety outcomes until initiation of a subsequent DMT. The EDSS was re‐baselined at 30 days from ALEM start (BL EDSS).
Results
Eighty‐seven ALEM‐treated patients (median age: 32 years, 72% female, 14% treatment‐naïve) were followed for a median of 55 (interquartile range 31–68) months. We found significant reductions in the ARR from 1.16 before ALEM to 0.15 throughout Years 1–9 ( p < 0.001). Subsequent DMTs were initiated in 19 patients (22%, 74% anti‐CD20 monoclonal antibodies). At Year 5 ( n = 53), more patients achieved CDI (58%, 95% confidence interval (CI) 45%–71%) than had experienced PIRA (14%, CI 7.5%–24%), and 58% remained relapse‐free. Shorter MS duration ( p < 0.001, hazard ratio (HR) 0.86 (CI 0.80–0.93)) and no previous high‐efficacy treatment ( p < 0.001, HR 5.16 (CI 2.66–10.0)) were the best predictors of CDI, while PIRA was associated with a higher number of previous DMTs ( p = 0.04, HR 3.06, CI 1.05–8.89). We found no new safety signals.
Interpretation
ALEM had long‐lasting beneficial effects on the ARR and disability improvement, especially when initiated early in the course of the disease. Only a subset of patients received subsequent DMTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
- Department of Ophthalmology and Optometry, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria.
- Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University, Salzburg, Austria.
- Department of Research and Innovation, Team Biostatistics and Publication of Clinical Trials, Paracelsus Medical University, Salzburg, Austria.
- Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.
- Department of Neurology and Comprehensive Center for Clinical Neurosciences and Mental Health, both Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Tobias Moser, Gabriel Bsteh, Barbara Kornek, Johann Sellner
Zitieren
APA
Moser, T., Foettinger, F., Hitzl, W., Novotna, B., Berger, T., Bsteh, G., Di Pauli, F., Hegen, H., Kornek, B., Langenscheidt, D., & Sellner, J. (2024). Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52056
Vancouver
Moser T, Foettinger F, Hitzl W, Novotna B, Berger T, Bsteh G, et al. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52056
BibTeX
@article{Moser2024,
author = {Moser, Tobias and Foettinger, Fabian and Hitzl, Wolfgang and Novotna, Bianka and Berger, Thomas and Bsteh, Gabriel and Di Pauli, Franziska and Hegen, Harald and Kornek, Barbara and Langenscheidt, Dieter and Sellner, Johann},
title = {Alemtuzumab treatment for multiple sclerosis in Austria: An observational long‐term outcome study},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52056}
}
EUVIMED